|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | In vivo visualization of phagocytotic cells in rat brains after transient ischemia by USPIO显示文摘 | Rausch M Baumann D Neubacher U | 2002 | NMR Biomed2002，15，4： | 1 |
| 2 | Cardiovascular (CV) safety of linagliptin in patients with type 2 diabetes (T2D):a pooled comprehensive analysis of prospectively adjudicated CV events in phase 3 studies显示文摘 | Johansen OE Neubacher D Seck T | 2013 | Diabetes2013，62，1： | 1 |
| 3 | Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a prespecified,prospective,and adjudicated meta-analysis of a phase 3 programme显示文摘 | Johansen OE Neubacher D von Eynatten M | 2012 | Cardiovasc Diabetol2012，11，3： | 1 |
| 4 | Car- diovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and ad- judicated meta-analysis of a phase 3 programme 显示文摘 | Johansen OE Neubacher D yon Eynatten M | 2012 | Cardiovasc Diabetol2012，11，： | 1 |
| 5 | Cardiovascularsafety with linagliptin in patients with type 2 diabetes mellitus:apre-specified,prospective,and adjudicated meta-analysis of a phase3 programme显示文摘 | Johansen OE Neubacher D von Eynathen M | 2012 | Cardiovasc Diabetol2012，11，： | 1 |
| 6 | Cardiovas cular safety with linagliptin in patients with type 2diabetes mellitus:aprespecified,prospective and adjudicated meta-analysis ofa phase 3 pro gramme显示文摘 | Johansen OE Neubacher D von Eynatten M | 2012 | Cardiovasc Diabetol2012，11，3： | 1 |
| 7 | Cardivasu- lar safety with Linagliptinin patients with type2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysisof- phase3 programme显示文摘 | Johansen OE Neubacher D yon Evnatten M | 2012 | Cardivasc Diabetol2012，11，： | 1 |
| 8 | Manipulation of shock/boundary-layer interactions in hypersonic inlets显示文摘 | Schulte D Henckels A Neubacher R | 2001 | Journal of Propulsion and Power2001，17，3： | 1 |
| 9 | Spectrometric measurement in laryngeal cancer显示文摘 | Arens C Reussner D Neubacher H | 2006 | Eur Arch Otorhinolaryngol2006，263，11： | 1 |
| 10 | Safety and efficacy of linagliptin in combination with basal insulin: a pre-specified, pooled analysis in a vulnerable population of elderly patients ( age ≥70 years) with type 2 diabetes显示文摘 | yon Eynatten M Neubacher D Stat D | 2012 | Endocr Rev2012，33，： | 1 |
| 11 | Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta- analysis of a phase 3 programme 显示文摘 | JOHANSEN OE NEUBACHER D yon EYNATTEN M | 2012 | Cardiovase Diabetol2012，11，： | 1 |
| 12 | Cardio vascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta- analysis of a phase 3 progTamme显示文摘 | Johansen OE Neubacher D van Eynatten M | 2012 | Cardiovasc Diabetol2012，11，： | 1 |
| 13 | Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme显示文摘 | Johansen OE Neubacher D von Eynatten M | 2012 | Cardiovasc Diabetol2012，11，： | 1 |
| 14 | Processing strategies and problems encountered in the use of dictionaries显示文摘 | | 1988 | In Dictionaries:Journal of the Dictionary Society of North America1988，10，： | 1 |
| 15 | Cardiovascular safety with linagliptin in patients with type 2 diabetes 显示文摘 | Johansen OE Neubacher D yon Eynatten M | 2012 | Cardiovasc Diabetol2012，11，3： | 1 |
| 16 | Efficacy and cardiovascular safety of linagliptin as an add-on to insulin in type 2 diabetes:a pooled comprehensive post hoc analysis显示文摘 | Zinman B Ahrén B Neubacher D | 2015 | Can J Diabetes2015，71，15： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员